Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70058 | 0.93 | TYR (0.51) | TYRHTTTSHRMEN1TP53 | |
| SCHEMBL71452 | 0.89 | TYR (0.49) | TYRHTTTSHRMEN1TP53 | |
| SCHEMBL10532360 | 0.86 | RORC (0.45) | TYRHTTTSHRMEN1TP53 | |
| SCHEMBL28638697 | 0.84 | SRC (0.60) | HTTTSHRMEN1TP53MAPT | |
| SCHEMBL18704829 | 0.84 | ESR1 (0.42) | TYRHTTTSHRMEN1TP53 | |
| SCHEMBL29477949 | 0.83 | SRC (0.59) | HTTTSHRMEN1TP53MAPT | |
| Potassium SCHEMBL29477955 | 0.83 | SRC (0.59) | HTTTSHRMEN1TP53MAPT | |
| SCHEMBL18986199 | 0.81 | TYR (0.49) | TYRSRC | |
| SCHEMBL1104213 | 0.81 | TSHR (0.61) | TYRTSHRALOX15 | |
| SCHEMBL29492442 | 0.81 | TSHR (0.61) | TYRTSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318217-B2 | Compositions comprising an anti-inflammatory blend | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120128613-A1 | COMPOSITIONS COMPRISING A SKIN-LIGHTENING RESORCINOL AND A SKIN DARKENING AGENT | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2012-05-24 | — | — | US | disclosed |
| US-20120128605-A1 | COMPOSITIONS COMPRISING A SKIN-LIGHTENING RESORCINOL AND A SKIN DARKENING AGENT | JOHNSON & JOHNSON CONSUMER INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120101156-A1 | COMPOSITIONS COMPRISING A RETINOID AND AN NFkB-INHIBITOR AND THEIR METHODS OF USE | KENVUE BRANDS LLC | 2012-04-26 | — | — | US | disclosed |
| US-20120064149-A1 | HIGH-CLARITY AQUEOUS CONCENTRATES OF 4-HEXYLRESORCINOL | JOHNSON KALONDA TYMIKA (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120045492-A1 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120045529-A1 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF | KENVUE BRANDS LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120045491-A1 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF | KENVUE BRANDS LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120045531-A1 | METHODS OF TREATING CELLULITE | KENVUE BRANDS LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120045407-A1 | COMPOSITIONS COMPRISING PAULOWNIN AND/OR PAULOWNIA EXTRACTS AND USES THEREOF | KENVUE BRANDS LLC | 2012-02-23 | — | — | US | disclosed |
| US-8084504-B2 | High-clarity aqueous concentrates of 4-hexylresorcinol | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8075930-B2 | Extracts of Phyllanthus niruri | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8075931-B2 | Extracts of Phyllanthus niruri | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110081431-A1 | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A NON-RETINOID COLLAGEN PROMOTER | KENVUE BRANDS LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082217-A1 | HIGH-CLARITY AQUEOUS CONCENTRATES OF 4-HEXYLRESORCINOL | KENVUE BRANDS LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110081430-A1 | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081433-A1 | COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND | JOHNSON & JOHNSON CONSUMER INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081305-A1 | COMPOSITIONS COMPRISING A SKIN-LIGHTENING RESORCINOL AND A SKIN DARKENING AGENT | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081308-A1 | EXTRACTS OF PHYLLANTHUS NIRURI | JOHNSON & JOHNSON CONSUMER INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081432-A1 | EXTRACTS OF PHYLLANTHUS NIRURI | JOHNSON & JOHNSON CONSUMER INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045492-A1 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF | CAT, TEX10, CD68 | TYR 596/4885HTT 1635/4885TSHR 4574/4885 |
| US-20120045491-A1 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF | CAT, TEX10, CD68 | TYR 596/4885HTT 1635/4885TSHR 4574/4885 |
| US-20110081431-A1 | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A NON-RETINOID COLLAGEN PROMOTER | NFKBIA, NFRKB, NFKB1 | TYR 4184/4885HTT 3686/4885TSHR 3297/4885 |
| US-20120045407-A1 | COMPOSITIONS COMPRISING PAULOWNIN AND/OR PAULOWNIA EXTRACTS AND USES THEREOF | PNN, CUTA, NCL | TYR 30/4885HTT 3270/4885TSHR 4845/4885 |
| US-20120128605-A1 | COMPOSITIONS COMPRISING A SKIN-LIGHTENING RESORCINOL AND A SKIN DARKENING AGENT | CUTA, NQO1, RBP4 | TYR 5/4885HTT 1074/4885TSHR 4410/4885 |
| US-20120045529-A1 | COMPOSITIONS COMPRISING PAULOWNIA TOMENTOSA WOOD EXTRACTS AND USES THEREOF | CAT, TEX10, CD68 | TYR 596/4885HTT 1635/4885TSHR 4574/4885 |
| US-20120101156-A1 | COMPOSITIONS COMPRISING A RETINOID AND AN NFkB-INHIBITOR AND THEIR METHODS OF USE | NFKBIA, NFKB2, NFKB1 | TYR 1074/4885HTT 3568/4885TSHR 4236/4885 |
| US-20120064149-A1 | HIGH-CLARITY AQUEOUS CONCENTRATES OF 4-HEXYLRESORCINOL | RFC4, RBP4, KEAP1 | TYR 838/4885HTT 16/4885TSHR 4235/4885 |
| US-20120045531-A1 | METHODS OF TREATING CELLULITE | CUTA, PYGM, FABP4 | TYR 159/4885HTT 4243/4885TSHR 4538/4885 |
| US-20110081430-A1 | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER | NFKBIA, NFKB1, NFKB2 | TYR 199/4885HTT 620/4885TSHR 4455/4885 |
| US-20110081308-A1 | EXTRACTS OF PHYLLANTHUS NIRURI | CUTA, COLGALT1, COL1A1 | TYR 224/4885HTT 2143/4885TSHR 4484/4885 |
| US-20110081433-A1 | COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND | NFKBIA, NFKB2, NFKB1 | TYR 2278/4885HTT 1636/4885TSHR 4885/4885 |
| US-20120128613-A1 | COMPOSITIONS COMPRISING A SKIN-LIGHTENING RESORCINOL AND A SKIN DARKENING AGENT | CUTA, NQO1, RBP4 | TYR 5/4885HTT 1074/4885TSHR 4410/4885 |
| US-20110082217-A1 | HIGH-CLARITY AQUEOUS CONCENTRATES OF 4-HEXYLRESORCINOL | RFC4, RBP4, KEAP1 | TYR 838/4885HTT 16/4885TSHR 4235/4885 |
| US-20110081432-A1 | EXTRACTS OF PHYLLANTHUS NIRURI | CUTA, COLGALT1, COL1A1 | TYR 224/4885HTT 2143/4885TSHR 4484/4885 |
| US-20110081305-A1 | COMPOSITIONS COMPRISING A SKIN-LIGHTENING RESORCINOL AND A SKIN DARKENING AGENT | CUTA, NQO1, RBP4 | TYR 5/4885HTT 1074/4885TSHR 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.